Navigation Links
Medizone International Takes Aim at the Bioterrorism Countermeasures Arena
Date:12/1/2009

SAN FRANCISCO, Dec. 1 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) announced today that in tests involving its proprietary AsepticSure(TM) technology, it continues to break "6 log" decontamination barriers, this time with two very different spore forming bacteria, Claustridium difficile and Bacillis subtilis. These results clearly establish AsepticSure(TM) as an extremely potent sporicidal technology. "The implications of a 6.7 log reduction (99.99997 %) in C difficile are indeed significant for the entire health care system," stated Dr Michael Shannon, Director of Medical Affairs for Medizone. "However, even though our findings for Bicillis subtilis are preliminary, the potential of being able to eliminate 99.999992% (7.2 log kill) of an internationally accepted surrogate for Anthrax in 90 minutes will have national security implications." In response to this news, Mr. Brad Goble, CEO of TDV GLOBAL and a Canadian leader in global health security and bio-terrorism countermeasures commented, "The international community continues to strengthen collaboration in the area of medical countermeasures, including placing a high priority on new and emerging technologies for decontamination. Medizone's early laboratory results with Bicillis subtilis will attract great interest from the global defense and public health portfolios alike." Medizone believes that a field hardened variant of the AsepticSure(TM) hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives.

Medizone's CEO Edwin Marshall added, "Following the impressive results recently announced for MRSA, we immediately began to assess the capability of AsepticSure(TM) using the same updated technology with the spore forming bacteria C difficile, which is ubiquitous within hospitals and chronic care centers. Following those results we then worked with Bicillis subtilis, which represents the infamous and highly lethal terrorist agent, Anthrax. In both cases, these two pathogens remain very resistant to standard decontamination procedures and hence, seeing our technology virtually annihilate these two difficult spore formers has lead Medizone to a parallel track of development with its AsepticSure(TM) technology which we are convinced will open up the possibility for commercialization in both arenas."

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Medizone's dedicated research laboratory located in Innovation Park at Queen's University in Kingston, Ontario, Canada is currently being doubled in size to accommodate full scale room testing of the AsepticSure(TM) system. Construction and full instrumentation of the expanded facility is expected to be completed over the next two weeks.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.


       Investor Relations: 415-868-0300 / web site: www.medizoneint.com
                     E-mail: operations @ medizoneint.com

SOURCE Medizone International, Inc.


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medizone International, Inc. Announces Establishment of Canadian Foundation for Global Health
2. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
3. Mercy Ships and MediSend International Partner to Deliver Hope and Healing
4. French Ambassador for International Investment to Visit Toronto December 11
5. French Ambassador for International Investment to Visit Chicago December 9 and 10
6. Wyle Personnel Take Part in Important Studies Aboard the International Space Station
7. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
8. Advanced Cell Technologys Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the 3rd International Conference on Cell Therapy
9. Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results
10. Daval International Awarded Orphan Drug Designation for Motor Neurone Disease Treatment
11. Microfluidics International Corporation Announces Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... ... to the scientific and clinical research community’s growing body of knowledge during its ... in the Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, ...
(Date:4/20/2017)... MN and Bethesda, MD (PRWEB) , ... April ... ... Advancing Innovation announce the formation of a unique intellectual property (IP) sharing and ... potential of their most promising inventions. A main component of this effort is ...
(Date:4/19/2017)... Yorba Linda, Ca (PRWEB) , ... April 18, 2017 , ... ... highlight new technological advances. This webinar, which is part of the Protein and ... NxT Flow Cytometer and outline where this technology fits in current and future applications. ...
(Date:4/19/2017)... (PRWEB) , ... April 19, 2017 , ... ... Clostridium difficile (C. diff) infections through education and advocacy. Founded in 2010 ... to a C. diff infection, the foundation has become the most-consulted source for ...
Breaking Biology Technology:
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):